tag:blogger.com,1999:blog-4519234397783312626.post7226963517369145228..comments2023-10-09T11:42:57.305-04:00Comments on Healthcare, etc.: Lessons from XigrisMarya Zilberberghttp://www.blogger.com/profile/16080475886113209344noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-4519234397783312626.post-38300976184853275942011-11-23T09:36:16.557-05:002011-11-23T09:36:16.557-05:00Dear Anonymous, the 28-day mortality is somewhat a...Dear Anonymous, the 28-day mortality is somewhat arbitrary and may or may not correlate with longer-term outcomes, I agree. I do think it all goes to my assertion that there is a persistent disconnect between what the FDA requires and the needs of clinicians and policy makers. This needs to be fixed, or at least the gap needs to narrow. <br /><br />I am very much looking forward to the full publication of PROWESS-SHOCK!Marya Zilberberghttps://www.blogger.com/profile/16080475886113209344noreply@blogger.comtag:blogger.com,1999:blog-4519234397783312626.post-13760288873231297382011-11-23T08:45:05.590-05:002011-11-23T08:45:05.590-05:0028 day mortality is a silly outcome in critical ca...28 day mortality is a silly outcome in critical care. I'll be interested to hear your thoughts when the 90-day end points are released for PROWESS-SHOCK and indeed show benefit.Anonymousnoreply@blogger.com